UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California, 90095, United States
NCT Number: NCT06448286
This phase III trial compares pH weighted chemical exchange saturation transfer (CEST) magnetic resonance imaging (MRI)-based surgical resections to standard of care surgical resections for the treatment of patients with glioblastoma. Standard of care therapy for glioblastoma is surgery to remove tumor tissue that enhances on standard MRI imaging, however, it has been shown that significant tumor burden exists in the region around the tumor tissue that does not enhance with standard MRI. MRI is a procedure in which radio waves and a powerful magnet linked to a computer are used to create detailed pictures of areas inside the body. These pictures can show the difference between normal and tumor tissue. CEST MRI is a technique that uses differences in the tissue environment, like protein concentration or intracellular pH, to generate contrast differences. CEST MRI may identify tumor tissue that does not enhance with standard of care MRI. PH weighted CEST MRI based surgical resection may be more effective compared to standard of care surgical resection in treating patients with glioblastoma.
Trial opening soon.
Get Notified18 year and older
All sexes
Interventional
Phase 3
Los Angeles, California, 90095, United States
PRIMARY OBJECTIVE:
I. To assess the efficacy of potential of hydrogen (pH) sensitive MRI based resections of glioblastoma.
SECONDARY OBJECTIVE:
I. To find surgical and adjuvant therapies to treat infiltrating glioblastoma cells.
OUTLINE: Patients are randomized to 1 of 2 groups.
GROUP I: Patients undergo surgical resection with standard intraoperative guidance using contrast-enhanced MRI. Patients also undergo post operative standard of care radiation therapy over 30 fractions and receive standard of care temozolomide orally (PO) for 6 weeks. Additionally, patients undergo MRI during follow up.
GROUP II: Patients undergo surgical resection with intraoperative guidance using CEST MRI. Patients also undergo post operative standard of care radiation therapy over 30 fractions and receive standard of care temozolomide PO for 6 weeks. Additionally, patients undergo MRI during follow up.
After completion of study treatment, patients are followed up at months 3, 6, 12, and 24.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Undergo CEST MRI
Other names: Chemical Exchange Saturation Transfer MRI
Undergo contrast-enhanced MRI
Other names: CONTRAST ENHANCED MRI, Contrast-enhanced MRI, MRI With Contrast
Undergo MRI
Other names: Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI
Undergo standard of care radiation therapy
Other names: Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation
Undergo surgical resection
Other names: Operation, Surgery, Surgery Type, Surgery, NOS, Surgical, Surgical Intervention, Surgical Interventions, Surgical Procedures, Type of Surgery
Given PO
Other names: CCRG-81045, Gliotem, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temizole, Temodal, Temodar, Temomedac, TMZ
Time frame: Up to 2 years
Multivariate cox and log rank tests will be used to compare progression free survival.
Time frame: Up to 2 years
Multivariate cox and log rank tests will be used to compare overall survival.
Time frame: Up to 2 years
Independent sample Chi-squared tests will be used to compare differences in surgical complication rate.
Time frame: Up to 2 years
Independent sample Chi-squared tests will be used to compare differences in post-operative Karnofsky performance scale changes. The Karnofsky Performance Status (KPS) is a standardized measure used to assess a patient's ability to perform everyday tasks. It ranges from 0 to 100, with higher scores indicating better function.
Contact information is provided by the study sponsor or research team.
Jonsson Comprehensive Cancer Center
Other
PH Weighted Chemical Exchange Saturation Transfer Based Surgical Resections of Glioblastoma
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07735819
Astrocytoma, Glioblastoma
Detroit, Michigan, United States
View Trial DetailsNCT07715097
Astrocytoma, Glioblastoma
View Trial DetailsNCT07689721
Astrocytoma, Brain Diseases
View Trial DetailsNCT07678138
Astrocytoma, Glioblastoma
View Trial Details